|Bid||29.75 x 300|
|Ask||29.80 x 700|
|Day's Range||29.57 - 30.08|
|52 Week Range||21.25 - 38.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.83|
Understanding Cellectis SA.’s (ENXTPA:ALCLS) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...
The most recent earnings update Cellectis SA.’s (NASDAQ:CLLS) released in December 2017 signalled that losses became smaller relative to the prrior year’s level as a result of recent tailwinds InvestorsRead More...
NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
- M&A and deal-making exploding in cell therapy space, demonstrating how important this field will be in coming 30 to 50 years. Allogene is the most recent example, with over a dozen candidates licensed ...
Dow Jones stock Pfizer is teaming up with a group of former Kite executives to take on Gilead and Novartis in advanced cancer treatments.
Pfizer Inc said on Tuesday it would take a 25 percent stake in Allogene Therapeutics to accelerate the development of CAR T cell therapies sourced from donors instead of patients. San Francisco-based Allogene specializes in allogeneic therapies that are engineered from cells of healthy donors, allowing them to be stored for "off-the-shelf" use and reducing the time patients must wait for treatment. Allogene is co-founded and led by former Kite Pharma executives, including its former chief executive, Arie Belldegrun, who sold Kite to Gilead Sciences Inc for $12 billion last year.
Cellectis SA.’s (ENXTPA:ALCLS) announced its latest earnings update in December 2017, which signalled that losses became smaller relative to the prrior year’s level – great news for investors Today IRead More...
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
NEW YORK, March 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Cellectis SA.’s (NASDAQ:CLLS): Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. TheRead More...
The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday. Cellectis said it intended to make the three patents available for future licensing deals.